Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 1
1998 1
1999 1
2002 1
2003 1
2004 2
2008 1
2009 1
2010 2
2014 1
2015 2
2016 6
2017 4
2018 6
2019 19
2020 25
2021 24
2022 11
2023 11
2024 9
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Wakelee H, et al. N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3. N Engl J Med. 2023. PMID: 37272513 Free PMC article. Clinical Trial.
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. Horn L, et al. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280641 Clinical Trial.
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Spicer JD, et al. Lancet. 2024 Sep 28;404(10459):1240-1252. doi: 10.1016/S0140-6736(24)01756-2. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288781 Clinical Trial.
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
Cortellini A, Brunetti L, Di Fazio GR, Garbo E, Pinato DJ, Naidoo J, Katz A, Loza M, Neal JW, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi JV, Montrone M, Owen DH, Signorelli D, Fidler MJ, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika NO, Napolitano A, Fulgenzi CAM, Grisanti S, Grossi F, D'Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O'Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis DL, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Lo Russo G, Rogado J, Moliner L, Biello F, Aboubakar Nana F, Dingemans AM, Aerts JGJV, Ferrara R, Torri V, Hejleh TA, Takada K, Naqash AR, Garassino M, … See abstract for full author list ➔ Cortellini A, et al. Among authors: signorelli d. J Immunother Cancer. 2025 Feb 4;13(2):e010674. doi: 10.1136/jitc-2024-010674. J Immunother Cancer. 2025. PMID: 39904562 Free PMC article.
Cognitive impairment and chemotherapy: a brief overview.
Vitali M, Ripamonti CI, Roila F, Proto C, Signorelli D, Imbimbo M, Corrao G, Brissa A, Rosaria G, de Braud F, Garassino MC, Lo Russo G. Vitali M, et al. Among authors: signorelli d. Crit Rev Oncol Hematol. 2017 Oct;118:7-14. doi: 10.1016/j.critrevonc.2017.08.001. Epub 2017 Aug 14. Crit Rev Oncol Hematol. 2017. PMID: 28917271 Review.
Treatment of lung large cell neuroendocrine carcinoma.
Lo Russo G, Pusceddu S, Proto C, Macerelli M, Signorelli D, Vitali M, Ganzinelli M, Gallucci R, Zilembo N, Platania M, Buzzoni R, de Braud F, Garassino MC. Lo Russo G, et al. Among authors: signorelli d. Tumour Biol. 2016 Jun;37(6):7047-57. doi: 10.1007/s13277-016-5003-4. Epub 2016 Mar 4. Tumour Biol. 2016. PMID: 26943800 Free article. Review.
Diagnosis and management of typical and atypical lung carcinoids.
Pusceddu S, Lo Russo G, Macerelli M, Proto C, Vitali M, Signorelli D, Ganzinelli M, Scanagatta P, Duranti L, Trama A, Buzzoni R, Pelosi G, Pastorino U, de Braud F, Garassino MC. Pusceddu S, et al. Among authors: signorelli d. Crit Rev Oncol Hematol. 2016 Apr;100:167-76. doi: 10.1016/j.critrevonc.2016.02.009. Epub 2016 Feb 18. Crit Rev Oncol Hematol. 2016. PMID: 26917456 Review.
119 results